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Purpose/Objective(s): We sought to assess the utility of docetaxel administered concurrently with
salvage radiation therapy (SRT) following postprostatectomy biochemical failure (BF).
Methods and materials: Men with postprostatectomy BF were accrued on a single-arm phase 2
clinical trial. SRT doses ranged from 64.8 to 70.2 Gy and were delivered in 1.8-Gy fractions to the
prostate bed alone as the clinical target volume with a þ1-cm uniform planning target volume
expansion. The primary endpoint was progression-free survival at 4 years compared with the
Stephenson nomogram estimate. Kaplan-Meier methods were used to assess late toxicity, BF, and
distant metastases. An unplanned matched-pair analysis was performed with 19 patients treated
with SRT alone.
Results: Nineteen men were accrued and treated. Median follow-up was 4.8 years. Median pre-RT
prostate-speciﬁc antigen level was 0.7 ng/mL (interquartile range, 0.4-1.3 ng/mL). All 8 cycles ofConﬂicts of interest: Docetaxel was supplied by Sanoﬁ-Aventis, and this trial was supported by a grant from Sanoﬁ-Aventis to The University of
Michigan Medical Center for the performance of this investigator-initiated trial.
* Corresponding author. 1500 E. Medical Center Drive, Ann Arbor, MI 49019.
E-mail address: dhamm@med.umich.edu (D.A. Hamstra).
http://dx.doi.org/10.1016/j.adro.2015.11.001
2452-1094/Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for Radiation Oncology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
60 W.C. Jackson et al Advances in Radiation Oncology: JanuaryeMarch 2016docetaxel were completed in 17 (89%) patients. Acute grade 1-4 toxicities were observed in 79%,
50%, 58%, and 11%, respectively. A total of 68% of acute grade 1 toxicities were related to fatigue,
urinary, or bowel symptoms. For grade 2 toxicities, 76% were related to neutropenia, fatigue, or
urinary symptoms. Acute grade 3 and 4 toxicities were most commonly neutropenia (84% and
100%, respectively). All late toxicities were grade 1 to 2 with 89% related to bowel or urinary
function. Predicted 4-year progression-free survival was 39% and observed was 42% (90%
conﬁdence interval [CI], 24-60). Matched-pair analysis demonstrated no signiﬁcant improvement in
BF (PZ .96, hazard ratio, 0.98; 90% CI, 0.4-2.3) or distant metastases (PZ .09; hazard ratio, 0.3;
90% CI, 0.07-1.2), and no difference between late bowel (P Z .60) or urinary toxicity (P Z .41).
Conclusions: Docetaxel can safely be administered concurrently with SRT without signiﬁcantly
impacting posttreatment toxicity. Neutropenia was the most signiﬁcant acute toxicity. Given the
small sample size, no clear clinical beneﬁt was observed. Larger studies are needed to determine the
efﬁcacy of concurrent docetaxel in this setting.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostatectomy is the most common initial treatment for
men with localized prostate cancer. Although many men
have excellent long-term disease control following pros-
tatectomy, up to approximately 30% of men will have a
rising prostate-speciﬁc antigen (PSA) level post-
operatively.1 For men with a rising PSA level following
prostatectomy without evidence of metastatic progression,
salvage radiation therapy (SRT) is a standard treatment
option. Unfortunately, rates of recurrence following SRT
remain high with almost half of men who receive SRT
eventually experiencing disease progression,2 likely sec-
ondary either to the presence of micrometastatic disease at
the time of radiation therapy (RT) or to the failure of RT
to eradicate all disease within the deﬁned treatment ﬁeld.
Docetaxel, a taxane mitotic inhibitor, has been
demonstrated to improve overall survival for men with
androgen-independent metastatic prostate cancer and
more recently in men with newly diagnosed metastatic
prostate cancer.3-5 Additionally, docetaxel is a known
radiosensitizer. Radiosensitization is achieved through
docetaxel’s mechanism of action, which is to promote the
formation of stable microtubules and inhibit their disas-
sembly. This disruption of the normal microtubule func-
tion causes G2-M cell-cycle arrest, the most radiosensitive
phase of the cell cycle, and preclinical evidence supports
docetaxel as a favorable radiosensitizing agent.6
Given the role for docetaxel in treating metastatic
prostate cancer and its additional functionality as a radi-
osensitizer, we hypothesized that docetaxel administered
concurrently with SRT would improve the 4-year
progression-free survival (PFS) for men who experience
a rising PSA level postprostatectomy. On the basis of this
hypothesis we initiated a single-arm phase 2 clinical trial
assessing the safety and efﬁcacy of concurrent weekly
docetaxel combined with SRT for men who experienced arising PSA level postprostatectomy. Here, we report the
ﬁndings for treatment related toxicity, PFS, metastasis-
free survival, and quality of life (QOL).
Methods and Materials
Patient selection
This prospective single-arm phase 2 clinical trial
assessing concurrent docetaxel with SRT for men expe-
riencing a rising PSA level after prostatectomy was per-
formed at a single institution (registered with clinical
trials.gov, Identiﬁer: NCT00480857) and was approved
through the local institutional review board. All patients
provided written informed consent. Patients were enrolled
from March 2007 through May 2009; at that time, because
of a change in industry support, accrual was closed. Men
eligible for enrollment had a Karnofsky performance
status >80% with pathologically proven prostate adeno-
carcinoma from a prostatectomy specimen. Additionally,
patients were required to have biochemical evidence of
PSA recurrence following prostatectomy, as demonstrated
by a rising PSA level of at least 0.1 ng/mL between
2 consecutive measurements, and a serum PSA value
0.3 ng/mL. Hematologically, patients were required to
have an absolute neutrophil count >1500 cells/mm3,
platelets >100,000 cells/mm3, and hemoglobin >8.0 g/dL.
Men with evidence of metastatic disease present on
computed tomography or magnetic resonance imaging or
a positive radionuclide bone scan were excluded from
this trial, as were any patients receiving pharmacologic
androgen ablation following prostatectomy.
Treatment and follow-up
SRT was delivered to the prostate bed only as the
clinical target volume with a þ1-cm uniform expansion
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conformal RT with 6 MV photons. No patients
received additional treatment to the pelvis. SRT doses
ranged from 64.8 to 70.2 Gy and were delivered in 1.8-Gy
fractions. SRT dose was determined from the pre-SRT
PSA levels (<0.4 ng/mL, 0.4-1 ng/mL, and 1 ng/mL
were treated with 64.8 Gy, 68.4 Gy, and 70.2 Gy,
respectively). Docetaxel was supplied by Sanoﬁ-Aventis
and administered intravenously weekly at a dose of 20
mg/m2 in concurrent fashion with daily SRT for a total of
8 weeks. Patients received dexamethasone premedication
before each administration of docetaxel. Docetaxel was
held if the absolute neutrophil count was <1500 cells/
mm3 or platelets were <100,000 cells/mm3. Liver func-
tion was assessed on weeks 2, 4, 6, and 8 of treatment.
Patients were seen in follow-up 1 and 3 months after
completion of treatment, and every 3 months thereafter
for the ﬁrst year, every 6 months for the next 2 years, and
yearly thereafter. PSA values were collected at each
follow-up visit, and patients were also requested to
complete an Expanded Prostate Index Composite (EPIC)
questionnaire7 at follow-up appointments as per standard
clinical practice.
Primary and secondary outcomes
The planned primary outcome was to assess the 4-year
progression-free proportion of patients treated with con-
current weekly docetaxel and SRT and to compare this
proportion with the expected 4-year PFS as estimated by
prostatectomy Gleason score, pre-SRT PSA, surgical
margin status, and postprostatectomy PSA doubling time as
described by Stephenson et al.8,9 Biochemical failure (BF)
was deﬁned as any PSA measurement after the completion
of SRT that was greater than the post-SRT PSA nadir plus
0.2 ng/mL (post-SRT nadir þ 0.2 ng/mL). Secondary out-
comes included rates of complete biochemical response, as
deﬁned by the achievement of a post-SRT PSA nadir <0.1
ng/mL, rates of acute and late toxicities, rates of local
recurrence-free survival, freedom from distant metastases
(DM), as well as prostate cancerespeciﬁc mortality and
overall mortality. Acute toxicities were deﬁned as having
occurred within 90 days of treatment end; late toxicities
were all toxicities present from this time point forward.
Toxicities were graded according to the Common Termi-
nology Criteria for Adverse Events, version 3.0. All recur-
rence and survival rates were calculated from the end date of
SRT. QOL was assessed using the EPIC questionnaire.
Statistical analysis
Planned study characteristics included an enrollment
size of n Z 44, with an estimated 20% improvement in
PFS at 4 years. This would have resulted in >80%
power to detect a difference of this magnitude using a1-sided test with an alpha of 0.05. However, accrual
was halted early with enrollment of 19 patients. Kaplan-
Meier methods were used to determine a 4-year estimate of
BF as well as to assess rates of DM, prostate cancere
speciﬁc mortality, and overall mortality and late toxicity.
In addition to planned analyses, an unplanned matched
pair analysis was performed. Nineteen patients treated
with SRT alone at the same institution were selected from
an institutional database of patients treated with SRT
between 1995 and 2007. These patients were matched on
Gleason score, surgical margin status, postprostatectomy
PSA doubling time, pre-SRT PSA, and age at SRT, while
blinding for all clinical outcomes. Patients who could not
be matched exactly were matched to remain in the same
terminal node from the Stephenson PFS estimate diagram
such that the resulting estimated 4-year PFS would be the
same for each patient’s match. Patient characteristics were
compared between the enrolled and matched patients
using the paired samples t test and McNemar c2 test
for continuous and categorical variables, respectively.
Kaplan-Meier methods were used to plot BF, DM, and
late toxicities between the enrolled and matched patients.
Proportional hazard models with sandwich estimates were
used to test and provide hazard ratios (HR) and conﬁ-
dence intervals (CI) comparing the treatment groups.
Last, QOL data were available for 16 of the 19 enrolled
patients on this trial. Results from the EPIC questionnaire
at approximately 2 years posttreatment were compared
between enrolled patients and all available patients treated
at the same institution with SRT alone during the same
period for whom 2-year posttreatment QOL data were
available (n Z 29). The independent samples t test was
used to compare QOL between the enrolled and historical
patients. Baseline QOL data were not available, as this was
not recorded as part of this clinical trial.
Results
Patient characteristics
Nineteen men were treated with concurrent docetaxel
and SRT. Median follow-up was 4.8 years (interquartile
range [IQR], 4.6-5.3). Complete patient characteristics for
the cohort of enrolled men as well as matched pairs can be
found in Table 1. Matched-pair patients were similar to
their enrolled counterparts across clinical, pathologic, and
treatment-related variables. Matched pairs had longer
follow-up than patients enrolled on the clinical trial;
however, this is not surprising given the longer period
over which matched patients were treated.
Toxicity
Seventeen of 19 patients (89%) completed all 8 cycles
of docetaxel. All but 1 of these patients received the full
Table 1 Patient characteristics
Enrolled patients (SRT þ docetaxel, n Z 19) Matched pairs (SRT alone, n Z 19) P value
Age at SRT
Median (minimum-maximum) 66.6 (43.6-78.9) 66.9 (49.3-76.1) .17
Follow-up post-SRT, y
Median (IQR) 4.7 (4.6-5.3) 6.1 (4.5-7.1) .04
Pre-SRT PSA (ng/mL)
Median (IQR) 0.7 (0.4-1.3) 0.5 (0.4-1.5) .07
Pre-SRT PSA doubling time, mo
Median (IQR) 9.5 (5.2-15.1) 11.8 (4.9-21.5) .6
Post-SRT PSA nadir (ng/mL)
Median (IQR) 0 (0-0.3) 0.1 (0.0-0.6) .3
PSA nadir 0.1 ng/dL
No. of patients (%) 12 (63.2%) 11 (57.9%) 1.0
SRT dose (Gy) .5
64.8 10.5% 26.3%
68.4 57.9% 47.4%
0.2 31.6% 26.3%
Gleason score .17
2-6 5.3% 21.0%
7 52.6% 47.4%
8-10 42.1% 31.6%
þSM 26.3% 31.6% 1.0a
SVI 15.8% 15.8% 1.0
ECE 21.1% 36.8% .4
þSM or SVI or ECE 50.0% 61.1% .6
þLN 5.3% 0.0% .9
ECE, extracapsular extension; IQR, interquartile range; LN, lymph node; PSA, prostate-speciﬁc antigen; SM, surgical margin; SRT, salvage radiation
therapy; SVI, seminal vesicle invasion.
a 1 SRT þ docetaxel patient is missing these data, but this did not impact the Stephenson calculation. This pair is excluded from the testing.
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not complete all 8 cycles, 1 patient completed 6 (possibly
related upper gastrointestinal bleed), whereas the other
completed 4 cycles (persistent neutropenia). Six patients
(32%) had documented serious adverse events. Four were
grade 3 lymphopenia, 1 was a grade 3 upper gastroin-
testinal bleed, and the last was grade 2 hematochezia. A
complete list of the types of acute toxicities experienced
by enrolled patients broken down by grade can be foundTable 2 SRT þ docetaxel acute toxicity summary by grade
Grade 1 (63%) Grade 2 (18%) G
Fatigue (n Z 12, 26%) Neutropenia (n Z 5, 38%) N
Bowel frequency/urgency/form
(n Z 9, 20%)
Fatigue (n Z 3, 23%) B
Urinary frequency/urgency
(n Z 6, 13%)
Urinary frequency/urgency
(n Z 2, 15%)
U
Other (n Z 6, 13%) Anemia (n Z 1, 8%)
Hematochezia (n Z 4, 9%) Rectal (n Z 1, 8%)
Neuropathy (n Z 4, 9%) Weight loss (n Z 1, 8%)
Thrombocytopenia (n Z 3, 7%)
Anemia (n Z 2, 4%)
GI, gastrointestinal; SRT, salvage radiation therapy.in Table 2. Overall, 79% of patients experienced at least 1
grade 1 toxicity during treatment, 50% experienced at
least 1 grade 2 toxicity, 58% had at least 1 grade 3
toxicity, and 2 patients experienced a grade 4 toxicity,
both of which were grade 4 neutropenia.
Late toxicities (>90 days from treatment end) were
less common, with the majority of late toxicities being
continuation of acute toxicities >90 days. All late toxic-
ities were either grade 1 or 2 in severity (68% grade 1). Arade 3 (16%) Grade 4 (3%)
eutropenia (n Z 11, 84%) Neutropenia (n Z 2, 100%)
owel frequency/urgency/form
(n Z 1, 8%)
pper GI bleed (n Z 1, 8%)
Table 3 SRT þ docetaxel late toxicity (no grade >2
toxicities observed)
Toxicity Grade 1, n
(% of patients)
Grade 2, n
(% of patients)
Bowel
Bowel frequency/
urgency/form
6 (31.6) 1 (5.3)
Proctitis 1 (5.3) 3 (15.8)
Rectal incontinence 1 (5.3) 1 (5.3)
Urinary
Worsening urinary
incontinence
3 (15.8) 0 (0)
Cystitis 0 (0) 2 (10.5)
Urinary hesitancy 1 (5.3) 1 (5.3)
Urinary urgency 2 (10.5) 0 (0)
Urinary stricture 0 (0) 1 (5.3)
Worsening erectile
dysfunction
2 (10.5) 0 (0)
Peripheral neuropathy 1 (5.3) 0 (0)
SRT, salvage radiation therapy.
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and urinary toxicities accounted for 88% of the late
toxicities.
PFS
Based on Gleason score, pre-SRT PSA, surgical
margin status, and PSA doubling time, the 4-year PFS
estimate per Stephenson et al8 for the patients enrolled
was 39.8%. Actual 4-year PFS was 42% (90% CI, 24-60).
There was no difference in rates of 4-year PFS or me-
tastases among patients with 1 or more of the features
seminal vesicle involvement, extracapsular extension, or
positive surgical margins compared with patients without
any of these features (48.8% vs 41.1%, P Z .75, and
73.9% vs 82.4%, P Z .34, respectively). Twelve of 19
patients (63.2%) obtained a complete biochemical
response (PSA nadir 0.1 ng/mL). To date, 8 patients
have not experienced a biochemical recurrence. All 7
patients who did not obtain a PSA nadir 0.1 ng/mL have
had a biochemical recurrence. No patients had evidence of
a local recurrence, and there were no clinical failures.
Only 1 patient enrolled on this trial has since died; this
was not related to prostate cancer. As such, prostate
cancerespeciﬁc and overall survival at 4 years following
treatment were 100% and 94.7%, respectively.
Matched-pair analysis
We next compared clinical outcomes and rates of late
grade 2þ toxicities between enrolled men and their
matched pairs (Fig 1 A-D). There was no statistically
signiﬁcant difference between the 2 groups with regard to
either late grade 2þ bowel or urinary toxicity (both P >
.4). For rates of BF and DM, there was no statistically
signiﬁcant difference between treatment groups for either
endpoint, although there appeared to be a trend favoring
docetaxel with regards to DM (P Z .09; HR, 0.29 [90%
CI, 0.07-1.22]).
Quality of life
Sixteen of 19 patients enrolled on the trial completed
posttreatment EPIC questionnaires during the course of
their follow-up, with all patients completing a question-
naire approximately 2-years posttreatment. Pretreatment
QOL was not obtained. These results were compared with
an institutional cohort of 29 patients treated with SRT to
the prostate bed alone during the same period who had
completed an EPIC questionnaire approximately 2 years
posttreatment (Table 4). Patients treated with docetaxel
did report signiﬁcantly decreased sexual scores compared
with the historical cohort treated without docetaxel
(P Z .03). However, overall docetaxel did not seem to
signiﬁcantly alter 2-year posttreatment QOL. Urinaryfunction scores, urinary bother scores, bowel scores,
hormone scores, and overall scores were nearly identical,
with no statistically signiﬁcant difference identiﬁed be-
tween the 2 groups with respect to these domains.Discussion
The use of docetaxel has been evaluated broadly in
prostate cancer, originally in men with advanced
androgen-independent disease and more contemporarily
in earlier disease stages. Initial enthusiasm for docetaxel
in the treatment of prostate cancer stemmed from 2 pro-
spective randomized trials demonstrating improved
overall survival among men with metastatic androgen-
independent disease with docetaxel-based therapy.4,5
Recently, preliminary results from the Eastern Coopera-
tive Oncology Group ChemoHormonal Therapy versus
Androgen Ablation Randomized Trial for Extensive
Disease in Prostate Cancer revealed that upfront use of
docetaxel combined with androgen deprivation therapy
(ADT) in men with newly diagnosed metastatic prostate
cancer improved overall survival compared with ADT
alone,3 although the same results were not obtained in a
smaller French trial.10
Given the beneﬁts seen in the metastatic setting,
multiple early-phase clinical trials have assessed the
addition of docetaxel to deﬁnitive RT plus ADT for the
treatment of localized high-risk prostate cancer because
these men have poor long-term outcomes even with the
addition of ADT to radiation. Results from these single-
arm studies demonstrate acceptable rates of early and late
toxicity and some preliminary evidence for improved
biochemical control compared with expected PSA relapse
Figure 1 (A) Freedom from grade 2þ late urinary toxicity (P Z .41) and (B) late rectal toxicity (P Z .60). Freedom from (C)
biochemical progression (HR, 098 [90% CI, 0.41-2.35], PZ .9648) and (D) from metastasis (HR 0.29 [90% CI, 0.07-1.22], PZ .918.
CI, conﬁdence interval; HR, hazard ratio; SRT, salvage radiation therapy.
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a combination of docetaxel, deﬁnitive RT, and ADT is
being assessed in the phase 3 randomized Radiation
Therapy Oncology Group (RTOG) 0521 trial with a
control arm of radiation plus ADT and a primary outcome
of overall survival.17 The trial met its accrual goal in
2009; preliminary results demonstrated an improvement
in 4-year overall survival (HR, 0.70; P Z .04) and
decreased cumulative incidence of metastases (P Z .05)
in favor of the addition of docetaxel, without demon-
strating any beneﬁt in rates of BF (P Z .19)
(NCT00288080).18
Men with rising PSA levels after prostatectomy are
also at high risk for biochemical recurrence and metastatic
progression.19 To our knowledge, our ﬁndings are the ﬁrst
dedicated report of docetaxel in combination with SRT
for men with a rising postprostatectomy PSA level. We
demonstrated that, although acute treatment-related
toxicities were common, grade 1 toxicities were most
commonly related to either fatigue, change in bowel fre-
quency/urgency/form, or urinary frequency/urgency, and
grade 2 toxicities were related to neutropenia, fatigue, or
change in urinary habits. The majority (87%) of grade 3-4
acute toxicities was related to neutropenia and was tran-
sient in nature. There were no cases of febrile neu-
tropenia. Late toxicities were less common and most
frequently were secondary to acute toxicities persisting
>90 days. More important, the rate of late urinary
toxicities do not appear to be signiﬁcantly increased withthe addition of docetaxel compared with previous reports
at 2 years posttreatment, with patients in our trial having a
10% rate of grade 2 or greater urinary toxicity at 2 years
compared with 7% as reported by Feng et al in a large
multi-institutional analysis of late toxicities following
postprostatectomy radiation.20 Bowel toxicity was
increased in our study with an estimated 22% of patients
having a grade 2 or greater toxicity at 2 years compared
with 3% as reported by Feng et al.20 The use of post-
prostatectomy docetaxel in combination with RT has also
recently been assessed in a small cohort of men receiving
adjuvant RT by Gutilla et al, who similarly showed an
acceptable toxicity proﬁle.13 Finally, 2-year posttreatment
QOL was comparable to patients treated at the same
institution over the same time frame except perhaps with
decreased sexual QOL; however, the lack of pretreatment
QOL signiﬁcantly limits the strength of this conclusion
and prospective validation is required. The impact of the
addition of docetaxel to ADT on sexual QOL has been
assessed in a group of men with hormone-naïve metastatic
prostate cancer and was not shown to have a negative
impact21; however, it is possible that in the absence of
concurrent ADT that docetaxel may have an impact on
sexual QOL. Future studies are needed to assess the
impact of docetaxel on QOL for men receiving post-
prostatectomy RT.
Though we were unable to demonstrate a statistically
signiﬁcant improvement in the rate of biochemical
recurrence compared with our 4-year predicted rate, this
Table 4 EPIC 2-y posttreatment quality of life scores
SRT þ docetaxel (n Z 16) SRT alone (n Z 29) P value
Years post-RT for QOL
Median (IQR) 2.2 (2.1-3.1) 2.3 (2.0-2.9) .6
Year of RP
Median (IQR) 2003 (1999-2006) 2003 (2002-2007) .4
SRT dose
Median (IQR) 68.4 (68.4-70.2) 68.4 (64.8-68.4) .01a
Urinary function score (out of 100)
Median (IQR) 66.8 (52.8-79.3) 69.9 (52.3-100) .5
Urinary bother score (out of 100)
Median (IQR) 93.8 (87.5-100) 93.8 (92.2-100) .6
Bowel score (out of 100)
Median (IQR) 97.9 (90.0-100) 100 (90.6-100) .9
Sexual score (out of 100)
Median (IQR) 5.0 (0-24.5) 36.1 (20.8-70.8) .03
Hormone score (out of 100)
Median (IQR) 100 (91.3-100) 100 (85.0-100) .8
Overall QOL score (out of 100)
Median (IQR) 78.4 (68.1-89.6) 82.1 (71.0-91.6) .3
IQR, interquartile range; QOL, quality of life; RP, radical prostatectomy; SRT, salvage radiation therapy.
a Statistically signiﬁcant difference between mean SRT dose (68.5 Gy for SRT þ docetaxel vs 66.9 Gy for SRT alone).
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underpowered to detect differences in rates of BF of our
expected magnitude, which was a 20% reduction in 4-
year rates of BF. Although we did not demonstrate a
statistically signiﬁcant difference in rates of distant
metastasis (0.3 [0.07-1.2]), our ﬁndings appear suggestive
that an impact of concurrent radiation and docetaxel on
development of metastatic disease may be present and
suggest further evaluation in a larger trial is warranted.
Given the ﬁndings of improved overall survival with
decreased rates of metastatic disease without affecting
rates of BF observed in the preliminary results of RTOG
0521, it is possible that our observed lack of beneﬁt with
regards to BF and trend toward decreased rates of
metastasis are characteristic of treatment with combined
RT and docetaxel.
Recently, the RTOG reported the results of a study
combining salvage radiation, concurrent 6-month
androgen ablation, and sequential adjuvant docetaxel
(RTOG 0621). This single-arm multi-institutional trial of
76 patients demonstrated an approximate 20% improve-
ment in the 3-year rate of freedom from BF compared
with historical controls.22 There were several key differ-
ences between the designs of RTOG 0621 and our pre-
sented trial. RTOG 0621 treated men with adjuvant
radiation combined with 6 months of concurrent ADT,
followed by sequential docetaxel, at a higher dosing than
we treated our patients with concurrently (75 mg/m2
every 21 days [RTOG 0621] vs 20 mg/m2 every week).
Although median pre-RT PSA levels were similar in both
studies (median 0.7 vs 0.6 ng/mL), 58% of patients in
ROTG 0621 had positive surgical margins compared withonly 26% in our study, and as such may have been more
likely to have disease localized to the prostate bed alone.
Additionally, multiple research groups have proposed that
treatment with taxanes impairs androgen receptor activ-
ity23-25; therefore, it is possible that there is a synergistic
effect when treating with the combination of ADT and
docetaxel and that this interaction drove the improvement
in freedom from BF observed in RTOG 0621. Although
we were unable to demonstrate any improvement in rates
of BF secondary to a lack of statistical power, given the
impressive rates of biochemical control in RTOG 0621,
future trials of docetaxel combined with salvage RT for
recurrent prostate cancer postprostatectomy are
warranted.
A notable ﬁnding in our analysis is that all men with a
PSA nadir >0.1 ng/mL experienced biochemical recur-
rence. The importance of reaching an undetectable nadir
following SRT has previously been highlighted, with
patients not achieving an undetectable nadir having
decreased overall survival.26,27
The major limitation of our study is the small sample
size which resulted in a lack of power to fully assess our
primary outcome of improvement in 4-year rate of BF.
Additionally, lack of baseline QOL data prevents com-
plete assessment of changes in QOL associated with
docetaxel therapy.
In closing, we demonstrate that concurrent docetaxel
with salvage radiation for men with a rising PSA level
following prostatectomy appears to be associated with
acceptable rates of acute toxicity, of which the most
signiﬁcant was neutropenia, low rates of late toxicity, and
minimal changes in overall QOL at 2-years posttreatment
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demonstrate improved efﬁcacy of concurrent docetaxel in
this setting, possibly because of early closure and a small
sample size. Nevertheless, the safety of this regimen as
well as the encouraging results with docetaxel combined
with ADT in the ChemoHormonal Therapy versus
Androgen Ablation Randomized Trial for Extensive
Disease in Prostate Cancer and radiation and ADT in
RTOG 0621 suggest that larger clinical trials may be
warranted to assess the efﬁcacy of docetaxel when
administered concurrently with salvage radiation
following prostatectomy.
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